LAUSR

BACKGROUND: Acute lymphoblastic leukemia (ALL) is a common cancer in children, and outcomes have greatly improved because of the refinement of multiagent chemotherapy regimens that include intensified asparaginase therapy. Asparaginase, a cornerstone of modern pediatric chemotherapy regimens for ALL and asparaginase‐containing protocols, is increasingly used in adolescent and adult patients historically treated with asparaginase‐free regimens. OBJECTIVES: This article is an overview of commonly encountered asparaginase‐associated toxicities and offers recommendations for treatment management. METHODS: A literature review was conducted, reviewing asparaginase and common toxicities, specifically hypersensitivity, pancreatitis, thrombosis, hyperbilirubinemia, and hyperglycemia. FINDINGS: The rapid identification and management of common asparaginase‐associated adverse events can reduce symptom severity and limit potential interruptions to therapy, possibly improving outcomes.